Gillian Ellison

TL;DR: EGFR gene copy number was a predictor of clinical benefit from gefitinib in ISEL, and the limited amount of data collected for KRAS and BRAF mutations prevented any meaningful evaluation of clinical outcomes in relation to these mutations.

TL;DR: Cytology samples including fine needle aspirate and pleural effusion can be used successfully to determine EGFR mutation status provided that sensitive testing methods are employed, and several different testing methods offer a more sensitive alternative to direct sequencing for the detection of common EGFR mutations.

TL;DR: In large tumor cell panels of diverse lineage, it is shown that MEK inhibitor response does not have an absolute correlation with mutational or phospho-protein markers of BRAF/MEK, RAS, or phosphoinositide 3-kinase (PI3K) activity.

TL;DR: ARMS was more sensitive and robust at detecting defined somatic mutations than DNA sequencing on clinical samples where the predominant sample type was FF-PET, and improved both the sensitivity and speed of analysis compared with sequencing.

TL;DR: MPE and plasma are valid surrogates for NSCLC tumour EGFR mutation detection when tissue is not available and ARMS is most suitable for mutation detection in tissue and MPE cell blocks; however, mutant-specific IHC could be a complementary method when DNA-based molecular testing is unavailable.